Navigation Links
High insulin levels tied to obesity pathway, new UT Southwestern research shows
Date:8/25/2014

UT Southwestern Medical Center researchers have identified a crucial link between high levels of insulin and pathways that lead to obesity, a finding that may have important implications when treating diabetes.

Researchers with the UT Southwestern's Touchstone Center for Diabetes found that giving mice high levels of insulin, which is typically done to counter the effects of diabetes or insulin resistance in Type 2 diabetes, also fosters processes that lead to obesity.

The discovery was made by studying mice engineered to lack receptors for a hormone called glucagon.

Glucagon spurs the liver's production of glucose into the bloodstream and thus maintains the fuel supply for the brain. Insulin blocks the secretion of glucagon, opposes glucagon action on the liver, and instructs the body to take up glucose from the blood. Type 2 diabetics cannot respond properly to insulin and have uncontrolled glucagon production, thereby causing their livers to overproduce glucose, contributing to high blood-sugar levels. Insulin is often given to people with type 2 diabetes to try to overcome insulin-resistance and lower the levels of glucose in the bloodstream.

But insulin also signals the body to produce fat, so when given the high levels of insulin needed to control excess glucose, mice become fat, explained corresponding author Dr. Michael Roth, Professor of Biochemistry at UT Southwestern and a member of the Touchstone Diabetes Center.

"We found that mice lacking the receptor for glucagon cannot get fat unless they are given the high levels of insulin found in mice (and humans) that have type 2 diabetes," said Dr. Roth, who holds the Diane and Hal Brierley Distinguished Chair in Biomedical Research. "This result suggests that the high levels of insulin found in those who develop insulin resistance and type 2 diabetes are a contributor to obesity and its complications."

Dr. Roth cautioned that if this response also happens in humans, then treating patients with type 2 diabetes with higher than normal amounts of insulin could contribute to the development of obesity.

The findings suggest that physicians may need to reconsider use of intensive insulin therapy to control hyperglycemia (high blood-sugar levels) in obese, diabetic patients with hyperinsulinemia (overproduction of insulin). In addition, the findings suggest that suppressing glucagon action could prevent hyperinsulinemia, without causing diabetes. The research team found that suppressing glucagon in obese, insulin-resistant, type 2 diabetic mice reduced blood glucose back to normal levels.

Glucagon and insulin normally counteract each other as part of an ongoing effort to stabilize blood-sugar levels. The glucagon hormone is produced and released by the pancreas in response to low concentrations of insulin and, conversely, glucagon release is suppressed by high levels of insulin in the bloodstream. The balance between the two hormones is disrupted in type 2 diabetics by the insulin that is given to control high glucose levels. This excess insulin, in turn, causes the body to produce excess fat. The new findings lead the authors to suggest that the high insulin levels actually aggravate diabetes. The optimal therapy, they propose, should be diet restriction and reducing glucagon levels.

According to estimates of the World Health Organization (WHO), 347 million people worldwide have diabetes, 90 percent of whom are affected by type 2 diabetes. Although previously only seen in adults, type 2 diabetes is now occurring in children, and can include complications such as an increased risk of heart disease and stroke, nerve damage, and eye disease.


'/>"/>

Contact: Russell Rian
russell.rian@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert  

Related medicine news :

1. Do closed-loop insulin delivery systems improve blood glucose control in type 1 diabetes?
2. Human Insulin Market by Product Types and Brand Worth $42 Billion by 2019 - New Report by MarketsandMarkets
3. Sensitive acid sensor controls insulin production
4. University of Florida Startup Launches Million-dollar Indiegogo Campaign to Eliminate Painful Needle Injections for Insulin
5. A new way to generate insulin-producing cells in Type 1 diabetes
6. Human Insulin Market Worth $42 Billion by 2019 - New Report by MarketsandMarkets
7. Bionic pancreas outperforms insulin pump in adults, youth
8. Late-breaking observational data show patients with type 2 diabetes taking JANUVIA® (sitagliptin) and metformin initiated insulin therapy at a slower rate compared to patients taking a sulfonylurea and metformin
9. New post-hoc analysis shows patients with type 2 diabetes undergoing intensification of insulin therapy experienced less nighttime hypoglycemia while being treated with Januvia (Sitagliptin) compared to placebo
10. Insulin-producing beta cells from stem cells
11. Tips To Improve Insulin Sensitivity and Avoid Storing Carbohydrates as Fat Released by Health News Wires
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
High insulin levels tied to obesity pathway, new UT Southwestern research shows
(Date:6/22/2017)... ... ... Groove Ring is excited to announce they've partnered with Olympic runner Jared ... all-purpose rings. Whether you’re an athlete, adventurer, professional, or love to venture the great ... the rock face to the auto shop, Groove Ring is the world's first breathable ...
(Date:6/22/2017)... ... ... Despite its pervasiveness, many physicians are unfamiliar with how best to treat ... practice. Now, however, a timely review has been published in the Journal of ... NeuP and educating preclinical scientists on its diagnosis and choice of treatment. , The ...
(Date:6/22/2017)... ... 2017 , ... Vighter, a premier provider of Unconventional Medical ... PSC.1-2012. The company’s work in countries throughout Southwest Asia, South America, and the ... degraded. The PSC.1 standard was created to protect fundamental freedoms and human rights ...
(Date:6/22/2017)... ... June 23, 2017 , ... Rise Against ... on June 21, 2017, at the Emeryville Center of Community Life. More than ... the world. , Rise Against Hunger (formerly Stop Hunger Now) meal packaging events ...
(Date:6/20/2017)... MA (PRWEB) , ... June 20, 2017 , ... ... and CHRISTUS Health, a Texas-based health system, will present how predictive analytics drive ... annual HFMA ANI meeting in Orlando, June 25-28. , “The traditional approach ...
Breaking Medicine News(10 mins):
(Date:6/5/2017)... June 5, 2017 The Cincinnati ... Diplomat Pharmacy, Inc. (NYSE: DPLO), has been awarded a ... . Results are based on an employee survey ... health and workplace improvement. The survey measures several aspects of ... ...
(Date:6/1/2017)... BELL, Pa. , June 1, 2017 ... (PRN) and Veterinarian Recommended Solutions (VRS), and KD Pharma ... investment in Nutriceutical Holdings by KD Pharma Group. KD ... Holdings with the option to acquire the entire company. ... partner in KD. They are committed to growing the ...
(Date:5/29/2017)... Biotechnology Ltd. (NASDAQ: APOP ; TASE: APOP), a ... of stem cells, today provided a corporate update and ... 31 st , 2017. "We are ... of 2017," said Dr. Shai Yarkoni, Chief Executive Officer. ... the first blood cancer patient in the recently initiated ...
Breaking Medicine Technology: